Stock Market & Financial Investment News

News Breaks September 26, 2012 10:23 EDT FRX, AZN Analysts say AstraZeneca could target Forest Labs, FT Alphaville says With the arrival of AstraZeneca's (AZN) new CEO, speculation persists about the company targeting takeover candidates, and Forest Labs (FRX) has been mentioned as a suitable target by several analysts, according to FT Alphaville. Reference Link News For FRX;AZN From The Last 14 Days Check below for free stories on FRX;AZN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 09:29 EDT AZN AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). May 20, 2013 07:28 EDT FRX American Thoracic Society to hold a conference Subscribe for More Information 07:27 EDT FRX American Psychiatric Association to host annual meeting Subscribe for More Information May 17, 2013 10:36 EDT FRX, AZN Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information 08:41 EDT AZN Impax commenced shipment of authorized generic Zomig Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. May 14, 2013 07:24 EDT AZN EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:53 EDT AZN Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link 15:55 EDT AZN Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says Subscribe for More Information May 10, 2013 11:48 EDT AZN Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 10:00 EDT FRX On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. May 9, 2013 16:34 EDT FRX Forest Labs initiated with an Underperform at BMO Capital Subscribe for More Information 10:17 EDT AZN Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information 06:05 EDT FRX Forest Labs and Trevene to co-develop TRV027 for acute heart failure Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.